Solventum Cash Flow Statement
SOLV / Health Care|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Solventum generated $369M in operating cash flow and negative free cash flow of $10M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 30.6%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | $1.6B | $479.0M | $1.3B | $1.3B |
| Depreciation & Amortization | $489.0M | $555.0M | $561.0M | $578.0M |
| Operating Cash Flow | $369.0M | $1.2B | $1.9B | $1.7B |
| Capital Expenditures | $379.0M | $380.0M | $290.0M | $251.0M |
| Free Cash Flow | -$10.0M | $805.0M | $1.6B | $1.4B |
| FCF Margin | -0.1% | 9.8% | 19.8% | 17.6% |